CN1860121A - 用于预防和治疗癌症的取代咪唑并嘧啶 - Google Patents

用于预防和治疗癌症的取代咪唑并嘧啶 Download PDF

Info

Publication number
CN1860121A
CN1860121A CNA2004800279669A CN200480027966A CN1860121A CN 1860121 A CN1860121 A CN 1860121A CN A2004800279669 A CNA2004800279669 A CN A2004800279669A CN 200480027966 A CN200480027966 A CN 200480027966A CN 1860121 A CN1860121 A CN 1860121A
Authority
CN
China
Prior art keywords
phenyl
pyrimidine
imidazo
nmr
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CNA2004800279669A
Other languages
English (en)
Chinese (zh)
Inventor
J·L·卡特娜鲁伊斯
C·费雷伦斯加列米
A·费尔南德斯塞拉特
C·塞拉科马斯
D·巴尔萨罗佩斯
C·拉古纳斯阿纳尔
C·萨尔切多罗卡
A·费尔南德斯加西亚
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
L V A T S A Lab SA
Original Assignee
L V A T S A Lab SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by L V A T S A Lab SA filed Critical L V A T S A Lab SA
Publication of CN1860121A publication Critical patent/CN1860121A/zh
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
CNA2004800279669A 2003-07-30 2004-07-29 用于预防和治疗癌症的取代咪唑并嘧啶 Pending CN1860121A (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ES200301906 2003-07-30
ES200301906 2003-07-30

Publications (1)

Publication Number Publication Date
CN1860121A true CN1860121A (zh) 2006-11-08

Family

ID=34130555

Family Applications (1)

Application Number Title Priority Date Filing Date
CNA2004800279669A Pending CN1860121A (zh) 2003-07-30 2004-07-29 用于预防和治疗癌症的取代咪唑并嘧啶

Country Status (14)

Country Link
US (1) US20060189631A1 (enExample)
EP (1) EP1660500B1 (enExample)
JP (1) JP2007500160A (enExample)
KR (1) KR20060034303A (enExample)
CN (1) CN1860121A (enExample)
AT (1) ATE380816T1 (enExample)
AU (1) AU2004263297A1 (enExample)
BR (1) BRPI0412636A (enExample)
CA (1) CA2534292A1 (enExample)
DE (1) DE602004010680T2 (enExample)
EA (1) EA009038B1 (enExample)
ES (1) ES2298798T3 (enExample)
WO (1) WO2005014598A1 (enExample)
ZA (1) ZA200601706B (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012159565A1 (zh) * 2011-05-23 2012-11-29 南京英派药业有限公司 6-(芳基甲酰)咪唑并[1，2-a]嘧啶和6-(芳基甲酰)[1，2，4]三唑并[4，3-a]嘧啶作为Hedgehog通路抑制剂及其应用

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007096764A2 (en) * 2006-02-27 2007-08-30 Glenmark Pharmaceuticals S.A. Bicyclic heteroaryl derivatives as cannabinoid receptor modulators
TW200817410A (en) 2006-08-07 2008-04-16 Incyte Corp Triazolotriazines as kinase inhibitors
EP2497470B8 (en) 2006-11-22 2015-12-02 Incyte Holdings Corporation Imidazotriazines and imidazopyrimidines as kinase inhibitors
PA8793301A1 (es) 2007-08-14 2009-04-23 Bayer Schering Pharma Ag Imidazoles bicíclicos fusionados
EP2062893A1 (en) * 2007-10-18 2009-05-27 Bayer Schering Pharma AG Fused imidazoles for cancer treatment
NZ589622A (en) 2008-05-21 2012-10-26 Incyte Corp Salts of 2-fluoro-N-methyl-4-[7-(quinolin-6-yl-methyl)-imidazo[1,2-b][1,2,4]triazin-2-yl]benzamide and processes related to preparing the same
NZ599289A (en) 2009-10-16 2014-11-28 Melinta Therapeutics Inc Antimicrobial compounds and methods of making and using the same
KR101870878B1 (ko) 2010-02-03 2018-06-25 인사이트 홀딩스 코포레이션 Ｃ―ＭＥＴ 억제제로서의 이미다조〔１，２―ｂ〕〔１，２，４〕트리아진
US8410117B2 (en) * 2010-03-26 2013-04-02 Hoffmann-La Roche Inc. Imidazopyrimidine derivatives
AU2012238589B2 (en) 2011-04-07 2017-02-16 Bayer Intellectual Property Gmbh Imidazopyridazines as Akt kinase inhibitors
US9186361B2 (en) 2013-03-15 2015-11-17 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
UY35400A (es) * 2013-03-15 2014-10-31 Novartis Ag Compuestos y composiciones para el tratamiento de enfermedades parasitarias
US9296754B2 (en) 2013-03-15 2016-03-29 Novartis Ag Compounds and compositions for the treatment of parasitic diseases
WO2014151630A2 (en) 2013-03-15 2014-09-25 Irm Llc Compounds and compositions for the treatment of parasitic diseases
PE20160865A1 (es) 2013-12-19 2016-09-03 Novartis Ag Derivados de [1,2,4] triazolo [1,5-a]pirimidina como inhibidores de proteasoma para el tratamiento de enfermedades parasitarias tales como leishmaniasis
JP2018507881A (ja) 2015-03-11 2018-03-22 メリンタ セラピューティクス，インコーポレイテッド 抗微生物化合物ならびにこれらを作製および使用する方法
CA3023317A1 (en) 2016-05-06 2017-11-09 Melinta Therapeutics, Inc. Antimicrobials and methods of making and using same

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3455924A (en) * 1967-02-08 1969-07-15 Upjohn Co Dianisylimidazoles
US5700826A (en) * 1995-06-07 1997-12-23 Ontogen Corporation 1,2,4,5-tetra substituted imidazoles as modulators of multi-drug resistance
ES2140354B1 (es) * 1998-08-03 2000-11-01 S A L V A T Lab Sa Imidazo (1,2a) azinas sustituidas como inhibidores selectivos de la cox-2.

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2012159565A1 (zh) * 2011-05-23 2012-11-29 南京英派药业有限公司 6-(芳基甲酰)咪唑并[1，2-a]嘧啶和6-(芳基甲酰)[1，2，4]三唑并[4，3-a]嘧啶作为Hedgehog通路抑制剂及其应用

Also Published As

Publication number Publication date
AU2004263297A1 (en) 2005-02-17
CA2534292A1 (en) 2005-02-17
JP2007500160A (ja) 2007-01-11
ATE380816T1 (de) 2007-12-15
DE602004010680D1 (de) 2008-01-24
DE602004010680T2 (de) 2009-01-02
EA009038B1 (ru) 2007-10-26
EP1660500B1 (en) 2007-12-12
ZA200601706B (en) 2007-09-26
KR20060034303A (ko) 2006-04-21
EA200600330A1 (ru) 2006-08-25
US20060189631A1 (en) 2006-08-24
ES2298798T3 (es) 2008-05-16
EP1660500A1 (en) 2006-05-31
WO2005014598A1 (en) 2005-02-17
BRPI0412636A (pt) 2006-09-26

Similar Documents

Publication Publication Date Title
CN1860121A (zh) 用于预防和治疗癌症的取代咪唑并嘧啶
US10426760B2 (en) Compounds and methods for kinase modulation, and indications therefor
KR102403287B1 (ko) 헤테로고리 화합물
US8153641B2 (en) Compounds and methods for kinase modulation, and indications therefor
US8110576B2 (en) Substituted pyrrolo[2,3b]pyrazines and methods for treatment of raf protein kinase-mediated indications
US8119637B2 (en) Substituted pyrrolo[2,3-b]pyrazines and methods for kinase modulation, and indications therefor
JP5208962B2 (ja) 二環式ピリミジノンおよびその使用
TWI693220B (zh) １,３,４-噻二唑化合物及其用於治療癌症之用途
AU2018200271A1 (en) Compounds
CN102647904A (zh) 新型三环蛋白激酶调节剂
CA2901805A1 (en) 4-substituted pyrrolo- and pyrazolo-diazepines
JP2012517426A (ja) ピロロピリミジニルａｘｌキナーゼ阻害剤
JPWO2009096435A1 (ja) 縮合複素環誘導体およびその用途
CN1458933A (zh) 噻吩并嘧啶化合物及其盐以及其制备方法
JP7413346B2 (ja) ピロロピラゾール誘導体
CN1830964A (zh) 4－取代苯氨基－3－硝基喹啉类化合物及其制备方法和用途
N’ta Ambeu et al. Microwave synthesis of new 3-(3-aminopropyl)-5-arylidene-2-thioxo-1, 3-thiazolidine-4-ones as potential Ser/Thr protein kinase inhibitors
US20240150277A1 (en) Covalent PPARG inverse-agonists
JP2017505821A (ja) 置換トリアゾロベンゾジアゼピン
MXPA06001262A (en) Substituted imidazopyrimidines for the prevention and treatment of cancer
CN1769284A (zh) 取代 1h－吲哚－2－酮类化合物及其制备方法和用途

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
AD01 Patent right deemed abandoned
C20 Patent right or utility model deemed to be abandoned or is abandoned